OTCMKTS:AITB - AIT Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.09 +0.04 (+0.79 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$5.09
Today's Range$5.00 - $5.50
52-Week Range$2.05 - $5.50
Volume19,500 shs
Average Volume5,740 shs
Market Capitalization$43.77 million
P/E Ratio-1.69
Dividend YieldN/A
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.

Receive AITB News and Ratings via Email

Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:AITB



Sales & Book Value

Annual SalesN/A


Net Income$-18,040,000.00


Market Cap$43.77 million
OptionableNot Optionable

AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions

What is AIT Therapeutics' stock symbol?

AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."

How were AIT Therapeutics' earnings last quarter?

AIT Therapeutics Inc (OTCMKTS:AITB) posted its earnings results on Wednesday, February, 13th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History.

When is AIT Therapeutics' next earnings date?

AIT Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for AIT Therapeutics.

Has AIT Therapeutics been receiving favorable news coverage?

Media stories about AITB stock have trended neutral this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of AIT Therapeutics' key competitors?

Who are AIT Therapeutics' key executives?

AIT Therapeutics' management team includes the folowing people:
  • Mr. Steven Adam Lisi, CEO & Chairman (Age 48)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)
  • Mr. Douglas J. Beck, Chief Financial Officer (Age 58)
  • Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
  • Dr. Giora Davidai M.D., Chief Medical Officer

How do I buy shares of AIT Therapeutics?

Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AIT Therapeutics' stock price today?

One share of AITB stock can currently be purchased for approximately $5.09.

How big of a company is AIT Therapeutics?

AIT Therapeutics has a market capitalization of $43.77 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.

What is AIT Therapeutics' official website?

The official website for AIT Therapeutics is http://www.ait-therapeutics.com.

How can I contact AIT Therapeutics?

AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.

MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel